Mutational spectrum
Missense and nonsense mutations, splice site mutations, deletions, and insertions. Genomic rearrangements so far reported only for NPHP1 (homozygous deletions represent 495% mutations) and CEP290 (heterozygous multiexon deletion reported in a single patient). Marked allelic heterogeneity, with a large number of mutations, was reported in each of the 10 genes. Genephenotype correlations are known for selected genes (about 50% patients with COR phenotype and about 75% patients with COACH phenotype have mutations in CEP290 and TMEM67 genes, respectively).
Analytical methods
Direct sequencing of coding genomic regions and splice site junctions; multiplex microsatellite analysis for detection of NPHP1 homozygous deletion. Possibly, qPCR or targeted array-CGH for detection of genomic rearrangements in other genes.
Analytical validation
Direct sequencing of both DNA strands; verification of sequence and qPCR results in an independent experiment. 1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) No good population-based data on JSRD prevalence have been published. A likely underestimated frequency between 1/80 000 and 1/100 000 live births is based on unpublished data.
1.9 If applicable, prevalence in the ethnic group of investigated person In Ashkenazi Jews, the estimated carrier frequency of the founder mutation p.R73L in the TMEM216 gene is about 1%.
Diagnostic setting
Comment: The early detection of breathing abnormalities and/or oculomotor apraxia is suggestive of JS and related disorders. Definite diagnosis is made based on the identification of the characteristic hindbrain malformation on brain imaging, that is, the 'molar tooth sign' or its component features.
TEST CHARACTERISTICS
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Nearly 100%. A test for large deletions/duplications in genes other than NPHP1 should be considered, especially in patients in whom a single heterozygous mutation has been detected with conventional sequencing. The presence of deep intronic mutations is not explored with current screening methods. Negative predictive value:
2.2 Analytical specificity (proportion of negative tests if the genotype is not present) Nearly 100%.
Clinical sensitivity (proportion of positive tests if the disease is present)
The overall clinical sensitivity for JSRD can be estimated at o50%, although a comprehensive mutation screening of all known genes in a cohort of JSRD patients has not been reported to date. It is expected that several disease-causative genes still remain to be identified.
The clinical sensitivity can be dependent on variable factors, such as age or family history, and can be higher in selected clinical subgroups based on existing gene-phenotype correlates. For instance, B75% of patients with JSRD and congenital liver fibrosis (including COACH syndrome) carry mutations in the TMEM67 gene, and few additional patients are mutated either in RPGRIP1L or CC2D2A, raising the clinical sensitivity to 490% in this specific JSRD subgroup.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity is unknown, as a large number of patients with similar phenotypes (eg, cerebellar vermis hypoplasia without the molar tooth sign) have not been tested for mutations, and as mutations in JSRD-causative genes have been documented in patients with other conditions.
In particular, JSRD is allelic to the following disorders:
Meckel syndrome at five gene loci (TMEM216, CEP290, TMEM67, RPGRIP1L, and CC2D2A); Nephronophthisis and Senior-Løken syndrome at four gene loci (NPHP1, CEP290, TMEM67, and RPGRIP1L); Leber Congenital Amaurosis at one gene locus (CEP290); Oro-facio-digital type I syndrome at one gene locus (OFD1).
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
The penetrance of disease-associated mutations is 100%, with clinical variability. Multiorgan involvement, such as retinal, renal, or hepatic disease, may develop at a later age (for instance, retinal dystrophy may present with congenital blindness or with progressive retinopathy; juvenile nephronophthisis usually becomes symptomatic towards the end of the first decade of life; congenital hepatic fibrosis is also progressive and may manifest at a variable age).
2.6
Negative clinical predictive value (probability of not developing the disease if the test is negative) JSRD are congenital disorders, and the neurological phenotype associated with the brain malformation manifests either in the neonatal period (hypotonia, irregular breathing, and nystagmus) or in the first year (developmental delay and oculomotor apraxia). A particular facial phenotype (open mouth, protruded tongue, high-arched eyebrows, and anteverted nostrils) is commonly observed in infancy. Very rarely, mild phenotypes may remain undiagnosed for years. Proband in that family had been tested: If mutations with established pathogenic significance in a given gene have been detected in the proband, the probability for a relative (eg, a sibling) to develop the disease if the test is negative is negligible.
Proband in that family had not been tested:
If mutations with established pathogenic significance are not detected in the proband, the clinical predictive value of a negative genetic test is low (o50%), even if all known genes have been comprehensively screened, as not all JSRD-causative genes are known. Nevertheless, a one in four recurrence risk in the future pregnancies should be assigned.
CLINICAL UTILITY
3.1 (Differential) diagnostics: the tested person is clinically affected (To be answered if in 1.10 'A' was marked) 3.1.1 Can a diagnosis be made other than through a genetic test? 3.1.2 Describe the burden of alternative diagnostic methods to the patient Brain magnetic resonance imaging usually requires sedation or general anaesthesia in neonates and young children. Clinical diagnosis without brain imaging or genetic testing is nonspecific in many patients.
3.1.3
How is the cost effectiveness of alternative diagnostic methods to be judged? Brain magnetic resonance imaging is necessary and sufficient to diagnose JSRD based on the identification of the 'molar tooth sign' .
Will disease management be influenced by the result of a genetic test?
No & (continue with 3.1.4) Yes 2
Clinically 2 Imaging 2
Therapy (please describe) Therapy is foreseeable for specific complications of Joubert syndrome-related disorders; for instance, renal insufficiency related to nephronophthisis must be adequately managed and may eventually require dialysis or renal transplantation. Prognosis (please describe)
Mutations in distinct genes are preferentially associated with a very high incidence of hepatic fibrosis (TMEM67) or nephronophthisis (NPHP1, RPGRIP1L, and CEP290), two life-threatening complications of Joubert syndromerelated disorders.
Management (please describe)
Once the diagnosis of Joubert syndrome-related disorders is made, the extent of multiorgan involvement should be evaluated through an articulated diagnostic protocol. To this aim, the knowledge of the causative gene may help address the diagnostic workflow based on known gene-phenotype correlates. For instance, patients carrying mutations either in NPHP1, CEP290, or RPGRIP1L must undergo an accurate nephrologic follow-up from the first years of life that is needed to detect early signs of renal dysfunction and plan appropriate therapies. Similarly, TMEM67 mutations are nearly invariably associated with congenital liver fibrosis that should be adequately investigated and followed-up to prevent potential complications.
